News

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device

Leave a Comment / News /

Emeryville, California, June 26, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has earned CE Mark approval, allowing the Company to initiate marketing efforts and commercialization of its Cerene Cryotherapy Device (Cerene device) in Europe. The Cerene device is intended for endometrial cryoablation in […]

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device Read More »

Channel Medsystems® Completes Treatments in Largest Single-Arm Pivotal Study of Endometrial Ablation; Demonstrates Feasibility of Comfortable, Office-Based Procedure

Leave a Comment / News /

Emeryville, California, March 20, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the successful completion of the treatment phase in its CLARITY Pivotal Study. The goal of the CLARITY study is to evaluate the safety and effectiveness of the Cerene® Cryotherapy Device (Cerene device) in 242 women

Channel Medsystems® Completes Treatments in Largest Single-Arm Pivotal Study of Endometrial Ablation; Demonstrates Feasibility of Comfortable, Office-Based Procedure Read More »

Channel Medsystems Secures IDE Approval and Treats First Women in the CLARITY Pivotal Study

Leave a Comment / News /

Emeryville, California, November 14, 2016. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the treatment of the first subjects in the US phase of its CLARITY Pivotal Study. CLARITY is a multicenter study to evaluate the safety and effectiveness of the Cerene™ Cryotherapy Device for endometrial ablation in

Channel Medsystems Secures IDE Approval and Treats First Women in the CLARITY Pivotal Study Read More »

Channel Medsystems Secures $22 Million Series C Financing Led by Third Point Ventures Company Prepares to Initiate a Pivotal Study for its Novel, Office-Based Therapy for Women with Heavy Menstrual Bleeding

Leave a Comment / News /

San Francisco, California, August 31, 2015. Channel Medsystems today announced a $22 million Series C financing led by Third Point Ventures. Additional participants in the round included new investor Longwood Fund, joined by insiders Scientific Health Development, Aperture Venture Partners, InCube Ventures and Boston Scientific. Per the terms of this financing, Jason Hong, Ph.D., of

Channel Medsystems Secures $22 Million Series C Financing Led by Third Point Ventures Company Prepares to Initiate a Pivotal Study for its Novel, Office-Based Therapy for Women with Heavy Menstrual Bleeding Read More »